Register entry
- Registered sites
- 0
- Active NDC listings
- 5
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
55 active NDC listings: 5 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 5.
| Dosage form | NDCs |
|---|---|
| liquid | 4 |
| solution | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| lonza biologics porrino, s.l. | 5 |
Catalogue
Marketed products
5| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Datopotamab | liquid | 42098-0007DRUG FOR FURTHER PROCESSING |
| - | Eculizumab | liquid | 42098-0005DRUG FOR FURTHER PROCESSING |
| - | andexanet alfa | liquid | 42098-0006DRUG FOR FURTHER PROCESSING |
| - | ravulizumab | solution | 42098-0003DRUG FOR FURTHER PROCESSING |
| - | ravulizumab 100 mg/ml | liquid | 42098-0004DRUG FOR FURTHER PROCESSING |
Enquiry
Common questions
- Is Lonza Biologics Porrino, S.L. FDA approved?
- Lonza Biologics Porrino, S.L. holds no registered establishment of its own; 5 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Lonza Biologics Porrino, S.L. make?
- 5 products are listed under Lonza Biologics Porrino, S.L. in the openFDA NDC Directory, most often as liquid; solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.